Allovir Inc expected to post a loss of 43 cents a share - Earnings Preview

Kalaris Therapeutics

09/02/2024 14:01

* Allovir Inc  ALVR.OQ   ALVR.O  is expected to show no
change in
quarterly revenue when it reports  results on February 13
(estimated) for the period ending December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Allovir Inc is for a
loss
of 43 cents per share. 
    * The current average analyst rating on the shares is "sell"
and
the breakdown of recommendations is no "strong buy" or "buy," 2
"hold" and 3 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Allovir Inc
is
$1.00​, above​ its last closing price of $0.67. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.41       -0.42      -0.39     Beat    6.3
 Jun. 30 2023  -0.43       -0.45      -0.48     Missed  -6.7
 Mar. 31 2023  -0.46       -0.46      -0.44     Beat    5.4​
 Dec. 31 2022  -0.56       -0.54      -0.37     Beat    31.9
 ​​Sep.        -0.52       -0.53      -0.50     Beat    5.1
 30 2022                                                
 Jun. 30 2022  -0.73       -0.73      -0.69     Beat    5.5​
 Mar. 31 2022  -0.80       -0.80      -0.69     Beat    13.4
 Dec. 31 2021  -0.78       -0.81      -0.92     Missed  -13.1
 This summary was machine generated February 9 at 14:01 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)